ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $6,036,023 | +62.9% | 968,864 | +75.2% | 0.30% | +67.8% |
| Q3 2022 | $3,705,000 | +480.7% | 553,010 | +2332.1% | 0.18% | +742.9% |
| Q1 2021 | $638,000 | -41.5% | 22,738 | -45.7% | 0.02% | -61.8% |
| Q4 2020 | $1,090,000 | +122.0% | 41,910 | +217.4% | 0.06% | +66.7% |
| Q3 2020 | $491,000 | -91.3% | 13,203 | -88.1% | 0.03% | -90.6% |
| Q2 2020 | $5,672,000 | -12.7% | 110,550 | +1.5% | 0.35% | -24.8% |
| Q4 2019 | $6,498,000 | +1839.7% | 108,961 | +1342.8% | 0.47% | +1930.4% |
| Q3 2018 | $335,000 | -95.2% | 7,552 | -95.7% | 0.02% | -93.6% |
| Q2 2018 | $6,945,000 | -17.4% | 177,191 | +52.4% | 0.36% | 0.0% |
| Q1 2018 | $8,408,000 | -55.6% | 116,247 | -59.6% | 0.36% | -64.0% |
| Q4 2017 | $18,934,000 | +234.2% | 287,577 | +154.4% | 0.99% | +248.8% |
| Q3 2017 | $5,665,000 | -19.7% | 113,020 | -25.9% | 0.28% | -25.4% |
| Q2 2017 | $7,057,000 | +248.0% | 152,500 | -5.9% | 0.38% | +185.1% |
| Q4 2016 | $2,028,000 | – | 162,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |